The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease
Author:
Affiliation:
1. Department of Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter, UK.
Publisher
The Korean Academy of Tuberculosis and Respiratory Diseases
Subject
Infectious Diseases,Pulmonary and Respiratory Medicine
Link
https://synapse.koreamed.org/pdf/10.4046/trd.2017.0098
Reference52 articles.
1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
2. Bronchodilator reversibility testing in chronic obstructive pulmonary disease
3. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
4. The Volumetric Response to Bronchodilators in Stable Chronic Obstructive Pulmonary Disease
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol;International Journal of Chronic Obstructive Pulmonary Disease;2020-10
2. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies;Advances in Therapy;2020-05-27
3. Journal Club—COPD2020 Update. Global Initiative for Chronic Obstructive Lung Disease 2020 Report and the Journal of the COPD Foundation Special Edition, Moving to a New Definition for COPD: “COPDGene® 2019”;Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation;2020
4. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease;Journal of Comparative Effectiveness Research;2019-11
5. The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects;Therapeutic Advances in Respiratory Disease;2019-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3